Review finds major gaps in medication research for methamphetamine use disorder

This paper is a systematic review, not a new treatment trial. That means the researchers gathered and assessed existing research rather than assigning participants to take a medication themselves.

The review focused on medications being studied for methamphetamine use disorder, or MUD. It had two main goals: to describe how much research has been done and to see whether candidate medications were tested consistently across different stages of research.

Those stages are often called a translational development pipeline. In simple terms, that means starting with preclinical work, which can include laboratory or animal research, then studying a medication in controlled human laboratory settings, and finally testing it in clinical trials. The idea is to learn whether signals seen early in research match what happens when a treatment is tested in people seeking help.

The authors identified 36 randomized, double-blind, placebo-controlled clinical trials evaluating 25 candidate medications for MUD. In this type of trial, participants are assigned by chance to receive either the medication or a placebo, an inactive comparison. “Double-blind” means that participants and researchers do not know who received which option during the study. This design can help reduce bias when researchers measure outcomes.

But the review found that only five candidate medications had been evaluated in all three settings: preclinical research, human laboratory research, and clinical trials. Those medications were aripiprazole, bupropion, d-amphetamine, modafinil, and naltrexone.

Overall, most of the studies reviewed showed no change in methamphetamine use with treatment across the research settings. The authors wrote that the available evidence suggested a high degree of “negative predictive validity.” In everyday language, this means that when early studies did not show a useful effect, later studies often also did not show an effect.

That pattern does not mean the research pipeline has been fully proven. The authors said limitations at every stage kept them from fully confirming whether results lined up across settings. In particular, they noted a lack of evidence for positive predictive validity: whether an encouraging result in early research reliably predicts success in later clinical trials.

The review also emphasizes how limited the medication research has been. No pharmacotherapy, meaning a treatment using medication, has received FDA approval for MUD. The authors describe the research investment in medication development for MUD as poor and say relatively few clinical trials have sought new options.

The university news coverage said the review identified 25 candidate medications tested in randomized, double-blind, placebo-controlled trials. The journal abstract provides an important added detail: those 25 medications were examined in 36 separate trials. The supplied abstract does not provide trial-by-trial results, participant numbers, treatment lengths, side-effect findings, or follow-up periods. So it cannot show whether a particular medication might help a particular person.

The researchers call for future studies that identify useful treatment targets and medication classes, including medicines that might be repurposed as well as new ones. They also point to newer FDA guidance that includes evaluating outcomes other than complete abstinence. Future work will need to test candidate treatments rigorously and show whether benefits outweigh harms in clinical settings.

For now, the clearest finding is about the state of the evidence: medication research for MUD remains limited, and the available studies have not yet produced an FDA-approved medication.